Skip to Content

Generic Arestin Availability

Arestin is a brand name of minocycline topical, approved by the FDA in the following formulation(s):

ARESTIN (minocycline hydrochloride - powder, extended release;dental)

  • Manufacturer: ORAPHARMA
    Approval date: February 16, 2001
    Strength(s): EQ 1MG BASE [RLD]

Has a generic version of Arestin been approved?

No. There is currently no therapeutically equivalent version of Arestin available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arestin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dispensing apparatus and cartridge
    Patent 6,682,348
    Issued: January 27, 2004
    Inventor(s): James R.; Lawter & Michael G.; Lanzilotti & Mark; Bates & Gregory H.; Hunter
    Assignee(s): OraPharma, Inc.
    A device for the treatment of periodontal disease includes a handle that has a configuration familiar to dental professionals, and a cartridge, that is locked into the handle when use, typically delivery of a composition to a periodontal pocket is desired. The cartridge provides for effective delivery of compositions, such as agents, as its tip is deformable, typically from a circular to an oval shape so as to flatten. The deformation may be made, either manually, by the dental professional, or upon contact with teeth or other tissues, whereby this flattened tip can penetrate deeply into periodontal pockets for quick and direct application of the composition, for example, therapeutic agents.
    Patent expiration dates:
    • March 29, 2022
      ✓ 
      Drug product
  • Dispensing apparatus and cartridge with deformable tip
    Patent 7,699,609
    Issued: April 20, 2010
    Inventor(s): Lawter; James R. & Lanzilotti; Michael G. & Bates; Mark & Hunter; Gregory H.
    Assignee(s): Orapharma, Inc.
    A device for the treatment of periodontal disease. The device includes a handle that has a configuration familiar to dental professionals and a cartridge that is locked into the handle when use, typically delivery of a composition to a periodontal pocket, is desired. The cartridge provides for effective delivery of compositions, such as agents, as its tip is deformable, typically from a circular to an oval shape so as to flatten. The deformation may be made either manually, by the dental professional, or upon contact with teeth or other tissues, whereby this flattened tip can penetrate deeply into periodontal pockets for quick and direct application of the composition, for example, therapeutic agents.
    Patent expiration dates:
    • March 29, 2022
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide